文献速递眼底病与葡萄膜炎

ASCEND-Eye:omega-3脂肪酸对糖尿病视网膜病变的影响

ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.
PubMed 文献 · Ophthalmology · 2023-12-03

ASCEND-Eye是ASCEND双盲随机安慰剂对照试验的子研究,纳入15480名英国40岁以上糖尿病患者,每日1克omega-3脂肪酸(含460毫克二十碳五烯酸和380毫克二十二碳六烯酸)用于心血管事件一级预防。通过链接英国国家医疗服务体系糖尿病眼筛查项目记录,获得7360名参与者(占随机化人群48%)的数据,平均随访6.5年。omega-3脂肪酸组548例(14.8%)发生可转诊眼病事件,安慰剂组513例(13.9%),率比1.07(95%CI 0.95-1.20,P=0.29),组间无统计学显著差异;结论认为该数据排除了每日1克omega-3脂肪酸对糖尿病视网膜病变有任何临床意义的获益。

要点

  • 每日1克omega-3脂肪酸组可转诊眼病事件548例(14.8%),安慰剂组513例(13.9%),率比1.07(95%CI 0.95-1.20,P=0.29)。
  • 次要和三级结局(包括按基线糖尿病视网膜病变严重程度分层的可转诊眼病、视网膜病变分级任何进展、新发糖尿病性黄斑病变)组间事件比例均无统计学显著差异。
  • 作者结论认为,这些数据排除了每日1克omega-3脂肪酸对糖尿病视网膜病变有任何临床意义的获益。

核心结论

  • 作者结论认为,这些数据排除了每日1克omega-3脂肪酸对糖尿病视网膜病变有任何临床意义的获益。

研究设计与样本

  • ASCEND-Eye是ASCEND双盲、随机、安慰剂对照试验的子研究,ASCEND纳入15480名英国40岁以上糖尿病患者。
  • 干预为每日1克omega-3脂肪酸(含460毫克二十碳五烯酸和380毫克二十二碳六烯酸),用于严重心血管事件的一级预防。
  • 通过链接英格兰和威尔士的国家医疗服务体系糖尿病眼筛查项目电子记录,并通过病历回顾确认参与者报告的眼部事件。
  • 采用log-rank法和分层log-rank法进行意向性治疗分析,分析至主要结局的时间。
  • 获得7360名参与者(占ASCEND随机化人群48%)的链接数据,平均随访6.5年。

主要发现

  • 主要疗效终点为随机化后首次记录到可转诊疾病的时间,可转诊疾病为可转诊视网膜病变(R2或R3a/s)或可转诊黄斑病变(M1)的复合终点,依据英国国家筛查委员会定义的 grading 标准。
  • omega-3脂肪酸组548例(14.8%)发生可转诊疾病事件,安慰剂组513例(13.9%),率比1.07(95%CI 0.95-1.20,P=0.29)。
  • 次要和三级结局包括按基线糖尿病视网膜病变严重程度分层的可转诊疾病结局、视网膜病变分级的任何进展以及新发糖尿病性黄斑病变,组间事件比例均无统计学显著差异。

关键数值与推荐

  • 可转诊疾病定义为可转诊视网膜病变(R2或R3a/s)或可转诊黄斑病变(M1),基于英国国家筛查委员会定义的 grading 标准。
  • omega-3脂肪酸组可转诊疾病事件548例(14.8%) vs 安慰剂组513例(13.9%),率比1.07(95%CI 0.95-1.20,P=0.29)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 链接数据仅获得7360名参与者(占ASCEND随机化人群48%)。
  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preclinical studies support a protective role for omega-3 fatty acids (FAs) on diabetic retinopathy (DR), but these observations have not been confirmed in randomized trials. We present randomized evidence for the effects of omega-3 FAs on DR outcomes. DESIGN: A substudy of the A Study of Cardiovascular Events iN Diabetes (ASCEND) double-blind, randomized, placebo-controlled trial of 1 g omega-3 fatty acids (containing 460 mg eicosapentaenoic acid and 380 mg docosahexaenoic acid) daily for the primary prevention of serious cardiovascular events, in 15 480 UK adults at least 40 years of age, with diabetes. PARTICIPANTS: Fifteen thousand four hundred eighty adults at least 40 years of age from the United Kingdom with diabetes from the ASCEND cohort. METHODS: Linkage to electronic National Health Service Diabetic Eye Screening Programme records in England and Wales and confirmation of participant-reported eye events via medical record review. Log-rank and stratified log-rank methods were used for intention-to-treat analyses of time until the main outcomes of interest. MAIN OUTCOME MEASURES: The primary efficacy endpoint was time to the first postrandomization recording of referable disease, a composite of referable retinopathy (R2 or R3a/s) or referable maculopathy (M1) based on the grading criteria defined by the United Kingdom National Screening Committee. Secondary and tertiary outcomes included the referable disease outcome stratified by the severity of DR at baseline, any progression in retinopathy grade, and incident diabetic maculopathy. RESULTS: Linkage data were obtained for 7360 participants (48% of those who were randomized in ASCEND). During their mean follow-up of 6.5 years, 548 participants (14.8%) had a referable disease event in the omega-3 FAs group, compared with 513 participants (13.9%) in the placebo group (rate ratio, 1.07; 95% confidence interval, 0.95-1.20; P = 0.29). There were no statistically significant between-group differences in the proportion of events for either of the secondary or tertiary outcomes. CONCLUSIONS: Representing the largest prospective test of its kind to date, these data exclude any clinically meaningful benefits of 1 g daily omega-3 FAs on DR. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Sammons EL, Buck G, Bowman LJ, et al. ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy. Ophthalmology. 2023. PMID: 38052385. doi:10.1016/j.ophtha.2023.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。